Eledon Pharmaceuticals (ELDN) Price & Analysis

Compare

979 Followers

ELDN Stock Chart & Stats

$1.57

-$0.17(-3.66%)

At close: Jan 08 4:00 PM EST

$1.57

-$0.17(-3.66%)

Day’s Range― - ―

52-Week Range$1.35 - $4.98

Previous CloseN/A

Volume121.23K

Average Volume (3M)3.00M

Market Cap

$117.88M

Enterprise Value$162.85M

Total Cash (Recent Filing)$93.40M

Total Debt (Recent Filing)$722.00K

Price to Earnings (P/E)―

Beta1.36

Next Earnings

Mar 19, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding75,084,694

10 Day Avg. Volume1,022,438

30 Day Avg. Volume2,997,601

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.69

Price to Sales (P/S)0.00

P/FCF Ratio-4.23

Enterprise Value/Market Cap1.38

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.85K

Enterprise Value/Ebitda-1.76

Forecast

1Y Price Target

$7.75

Price Target Upside393.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.79

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FinancingEledon has completed a $57.5M financing to support the continued development of tegoprubart in transplantation.

Regulatory Approval PathwayTegoprubart doesn't need to demonstrate superiority over tacrolimus in efficacy to obtain regulatory approval.

Safety ProfileTegoprubart continues to demonstrate a differentiated safety profile relative to the current standard of care, with fewer opportunistic infections and lower rates of metabolic, neurologic, and cardiovascular toxicities.

Bears Say

Market PenetrationThe lack of eGFR superiority vs. tacrolimus is definitely a disappointment, leading to a reduction in market penetration assumptions for tegoprubart.

Eledon Pharmaceuticals News

Eledon Pharmaceuticals Reports Q3 2025 Financial Results

Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

ELDN

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

Eledon Pharmaceuticals (ELDN) announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant...

1M ago

ELDN

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

Guggenheim lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $8 from $9 and keeps a Buy...

1M ago

ELDN

Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals, with...

1M ago

ELDN

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

“The results from our Phase 2 BESTOW trial demonstrated tegoprubart’s excellent efficacy and safety, importantly avoiding many of...

1M ago

ELDN

Eledon Pharmaceuticals options imply 14.1% move in share price post-earnings

Pre-earnings options volume in Eledon Pharmaceuticals (ELDN) is normal with calls leading puts 37:1. Implied volatility suggests the...

1M ago

ELDN

Eledon Pharmaceuticals Announces $46.5M Public Offering

Eledon Pharmaceuticals ( ($ELDN) ) has provided an announcement. On November 12, 2025, Eledon Pharmaceuticals entered into an...

1M ago

ELDN

Eledon prices 15.15M shares at $1.65 in underwritten public offering

Eledon Pharmaceuticals (ELDN) announced the pricing of its underwritten public offering of 15,152,485 shares of its common stock...

1M ago

ELDN

Eledon Pharmaceuticals announces common stock, warrant offering, no amount given

Eledon Pharmaceuticals (ELDN) announced that it has commenced an underwritten public offering of shares of its common stock...

1M ago

ELDN

Eledon Pharmaceuticals options imply 8.0% move in share price post-earnings

Pre-earnings options volume in Eledon Pharmaceuticals (ELDN) is normal with puts leading calls 4:3. Implied volatility suggests the...

1M ago

ELDN

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Earnings reports, economic updates, and more are among the top stock market stories worth reading on Friday. ...

1M ago

AMD

Eledon Pharmaceuticals’ Tegoprubart: Promising Safety Profile and Market Potential Despite eGFR Setback

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals, with...

1M ago

ELDN

Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today?

Eledon Pharmaceuticals stock fell hard on Friday after the company released clinical trial results. ...

1M ago

ELDN

Eledon Pharmaceuticals Reports Promising Phase 2 Trial Results

Eledon Pharmaceuticals ( ($ELDN) ) has issued an announcement. On November 6, 2025, Eledon Pharmaceuticals announced the results...

1M ago

ELDN

ELDN FAQ

What was Eledon Pharmaceuticals’s price range in the past 12 months?

Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.98 in the past 12 months.

What is Eledon Pharmaceuticals’s market cap?

Eledon Pharmaceuticals’s market cap is $117.88M.

When is Eledon Pharmaceuticals’s upcoming earnings report date?

Eledon Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 89 days.

How were Eledon Pharmaceuticals’s earnings last quarter?

Eledon Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.036.

Is Eledon Pharmaceuticals overvalued?

According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eledon Pharmaceuticals pay dividends?

Eledon Pharmaceuticals does not currently pay dividends.

What is Eledon Pharmaceuticals’s EPS estimate?

Eledon Pharmaceuticals’s EPS estimate is -0.2.

How many shares outstanding does Eledon Pharmaceuticals have?

Eledon Pharmaceuticals has 75,084,694 shares outstanding.

What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?

Eledon Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -7.955%.

Which hedge fund is a major shareholder of Eledon Pharmaceuticals?

Currently, no hedge funds are holding shares in ELDN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Eledon Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-95.49%

Trailing 12-Months

Asset Growth

13.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. (ELDN) is a clinical stage biotechnology company focused on developing targeted therapies for patients with autoimmune and neurodegenerative diseases. The company operates primarily in the pharmaceuticals sector and its core product pipeline includes experimental drugs aimed at modulating the immune system, with a key focus on the anti-CD40 Ligand pathway to address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS).

Eledon Pharmaceuticals (ELDN) Earnings & Revenues

Historic Earnings Reports

ELDN Stock 12 Month Forecast

Average Price Target

$7.75

▲(393.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.756923076923077,5.193846153846154,5.630769230769231,6.067692307692308,6.504615384615384,6.941538461538462,7.378461538461538,7.815384615384616,8.252307692307692,8.689230769230768,9.126153846153846,9.563076923076924,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.583846153846154,4.8476923076923075,5.111538461538462,5.375384615384616,5.639230769230769,5.903076923076924,6.166923076923077,6.430769230769231,6.694615384615385,6.958461538461538,7.222307692307693,7.486153846153846,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.295384615384616,4.270769230769231,4.246153846153846,4.2215384615384615,4.196923076923077,4.172307692307692,4.147692307692308,4.1230769230769235,4.098461538461539,4.073846153846154,4.049230769230769,4.024615384615385,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >